Opinion
26dOpinion
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of ...
Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results